Drugmaker Novo Nordisk tested Wegovy on adults aged 45 years and older who were overweight or obese with a history of heart disease. The weekly shot reduced their risk of heart attacks and strokes.
A five-year study of more than 17,600 adults with cardiovascular disease found the risk of a heart attack or stroke was cut by 20% in those given a 2.4mg weekly dose of Wegovy.